After the demonstration almost 20 years ago that antibodies to CD2 are potent inhibitors of T cell function, this cell surface glycoprotein became one of the most intensively studied of all T cell antigens ([1][1])([2][2])([3][3]). The subsequent identification of LFA-3 (CD58) as a ligand for human
No takes yet. Share an insight, caveat, or question.
P. Anton van der Merwe (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: